KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 129 filers reported holding KEROS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,773,488 | -66.0% | 149,733 | -57.2% | 0.01% | -66.7% |
| Q2 2023 | $14,049,339 | +60.0% | 349,660 | +70.0% | 0.04% | +55.6% |
| Q1 2023 | $8,781,682 | -64.9% | 205,660 | -60.5% | 0.03% | -68.2% |
| Q4 2022 | $24,996,139 | +623.5% | 520,536 | +466.8% | 0.08% | +507.1% |
| Q3 2022 | $3,455,000 | -6.3% | 91,840 | +45.7% | 0.01% | -6.7% |
| Q4 2021 | $3,688,000 | -37.3% | 63,028 | -57.6% | 0.02% | -42.3% |
| Q3 2021 | $5,879,000 | -65.6% | 148,600 | -63.1% | 0.03% | -66.2% |
| Q2 2021 | $17,099,000 | +24.5% | 402,607 | +80.4% | 0.08% | +20.3% |
| Q1 2021 | $13,736,000 | -8.9% | 223,162 | +4.4% | 0.06% | -13.5% |
| Q4 2020 | $15,081,000 | +384.0% | 213,800 | +164.6% | 0.07% | +362.5% |
| Q3 2020 | $3,116,000 | -45.5% | 80,800 | -46.9% | 0.02% | -56.8% |
| Q2 2020 | $5,713,000 | – | 152,300 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 407,633 | $12,995,340 | 5.15% |
| Opaleye Management Inc. | 360,400 | $11,489,552 | 3.74% |
| Parkman Healthcare Partners LLC | 298,475 | $9,515,383 | 1.74% |
| BRAIDWELL LP | 1,357,309 | $43,271,011 | 1.37% |
| First Light Asset Management, LLC | 421,438 | $13,435,443 | 1.28% |
| Orbimed Advisors | 1,514,734 | $48,289,720 | 1.03% |
| Yiheng Capital Management, L.P. | 554,151 | $17,666,334 | 0.90% |
| Nantahala Capital Management | 328,781 | $10,481,538 | 0.90% |
| DAFNA Capital Management LLC | 65,961 | $2,102,837 | 0.65% |
| EDBI Pte Ltd | 10,105 | $322,147 | 0.35% |